Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CVL-354 KOR/MOR Occupancy Study
NCT05547542Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of icalcaprant in opioid use disorder (OUD) (2 cohorts), sponsored by Cerevel Therapeutics. Primary endpoints: Kappa Opioid Receptor Occupancy at Day 1 and Mu Opioid Receptor Occupancy at Day 1. Started Mar 2023; status: completed.
02
Drugs
icalcaprant
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05547542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547542.